X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3373) 3373
Publication (594) 594
Book Review (38) 38
Book Chapter (20) 20
Book / eBook (3) 3
Dissertation (3) 3
Conference Proceeding (2) 2
Data Set (1) 1
Magazine Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2609) 2609
index medicus (2424) 2424
oncology (1499) 1499
proto-oncogene proteins b-raf - genetics (1367) 1367
mutation (1271) 1271
melanoma (1129) 1129
cancer (1104) 1104
cell line, tumor (1001) 1001
animals (987) 987
proto-oncogene proteins b-raf - antagonists & inhibitors (764) 764
female (745) 745
melanoma - drug therapy (738) 738
braf (688) 688
kinases (688) 688
cell biology (629) 629
melanoma - genetics (629) 629
male (627) 627
mice (615) 615
signal transduction (584) 584
resistance (578) 578
apoptosis (564) 564
proto-oncogene proteins b-raf - metabolism (528) 528
antineoplastic agents - pharmacology (525) 525
protein kinase inhibitors - pharmacology (523) 523
tumors (504) 504
melanoma - pathology (495) 495
article (487) 487
vemurafenib (485) 485
antineoplastic agents - therapeutic use (478) 478
research (478) 478
proteins (459) 459
metastatic melanoma (444) 444
activation (443) 443
genetic aspects (441) 441
acquired-resistance (432) 432
phosphorylation (431) 431
middle aged (427) 427
neoplasms (420) 420
metastasis (418) 418
mutations (417) 417
b-raf (412) 412
biochemistry & molecular biology (394) 394
care and treatment (390) 390
drug resistance, neoplasm (372) 372
aged (369) 369
signal transduction - drug effects (360) 360
expression (358) 358
protein kinase inhibitors - therapeutic use (356) 356
health aspects (350) 350
cell proliferation - drug effects (339) 339
raf protein (336) 336
drug resistance (319) 319
multidisciplinary sciences (316) 316
apoptosis - drug effects (314) 314
adult (313) 313
sulfonamides - pharmacology (311) 311
gene expression (305) 305
drug resistance, neoplasm - genetics (303) 303
melanoma - metabolism (302) 302
raf (302) 302
indoles - pharmacology (300) 300
chemotherapy (296) 296
inhibition (293) 293
colorectal cancer (290) 290
pathway (289) 289
medicine (286) 286
research article (284) 284
gene mutations (280) 280
xenograft model antitumor assays (278) 278
extracellular signal-regulated kinase (272) 272
digestive system diseases (268) 268
map kinase (265) 265
survival (258) 258
analysis (256) 256
cancer therapies (255) 255
molecular targeted therapy (254) 254
cells (251) 251
map kinase signaling system - drug effects (249) 249
therapy (248) 248
inhibitors (247) 247
colorectal neoplasms - genetics (241) 241
skin neoplasms - drug therapy (241) 241
cell proliferation (238) 238
growth (237) 237
ras proteins - genetics (237) 237
pharmacology & pharmacy (232) 232
drug resistance, neoplasm - drug effects (226) 226
kinase (224) 224
sorafenib (224) 224
science (221) 221
prognosis (220) 220
skin neoplasms - genetics (220) 220
targeted therapy (212) 212
open-label (209) 209
skin neoplasms - pathology (209) 209
biology (208) 208
development and progression (208) 208
proto-oncogene proteins c-raf - metabolism (204) 204
sulfonamides - therapeutic use (203) 203
indoles - therapeutic use (201) 201
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3346) 3346
French (11) 11
German (7) 7
Chinese (6) 6
Czech (4) 4
Japanese (2) 2
Danish (1) 1
Korean (1) 1
Polish (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 12/2011, Volume 480, Issue 7377, pp. 387 - 390
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2014, Volume 20, Issue 7, pp. 1965 - 1977
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 03/2014, Volume 124, Issue 3, pp. 1406 - 1417
Journal Article
Cancer Research, ISSN 0008-5472, 04/2011, Volume 71, Issue 7, pp. 2750 - 2760
This study addresses the role of PTEN loss in intrinsic resistance to the BRAF inhibitor PLX4720. Immunohistochemical staining of a tissue array covering all... 
METASTATIC MELANOMA | APOPTOSIS | PROTEIN | ONCOLOGY | PHOSPHORYLATION | CUTANEOUS MELANOMA | RAF KINASE | CANCER | MEDIATES RESISTANCE | LINES | ERK | RNA, Small Interfering - genetics | Up-Regulation | Humans | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins - biosynthesis | Bcl-2-Like Protein 11 | Melanoma - genetics | Apoptosis Regulatory Proteins - genetics | Indoles - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins B-raf - metabolism | Apoptosis Regulatory Proteins - biosynthesis | Melanoma - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | PTEN Phosphohydrolase - deficiency | Membrane Proteins - genetics | PTEN Phosphohydrolase - biosynthesis | Proto-Oncogene Proteins - genetics | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Membrane Proteins - biosynthesis | Membrane Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Apoptosis Regulatory Proteins - antagonists & inhibitors | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Apoptosis - physiology | Mutation | RNA, Small Interfering - administration & dosage | PTEN | melanoma | BRAF | PLX4032 | therapy | resistance
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2012, Volume 18, Issue 9, pp. 2502 - 2514
Purpose: The clinical use of BRAF inhibitors is being hampered by the acquisition of drug resistance. This study shows the potential therapeutic use of the... 
BREAST-CANCER | MULTIPLE-MYELOMA | APOPTOSIS | PHASE-II TRIAL | TANESPIMYCIN 17-AAG | TRASTUZUMAB | ONCOLOGY | BIM | ACQUIRED-RESISTANCE | MELANOMA-CELLS | POTENTIAL MECHANISM | Prospective Studies | Apoptosis - drug effects | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Immunoenzyme Techniques | Forkhead Transcription Factors - metabolism | Colony-Forming Units Assay | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Phthalic Acids - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Real-Time Polymerase Chain Reaction | Proto-Oncogene Proteins B-raf - metabolism | Membrane Proteins - genetics | Melanoma - pathology | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Apoptosis Regulatory Proteins - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Indoles - adverse effects | Membrane Proteins - antagonists & inhibitors | Signal Transduction - drug effects | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Cell Line, Tumor | HSP90 Heat-Shock Proteins - metabolism | Mice | Mice, Inbred BALB C | Forkhead Box Protein O3 | Azabicyclo Compounds - pharmacology | Phosphatidylinositol 3-Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - genetics | Proto-Oncogene Proteins c-akt - genetics | Proto-Oncogene Proteins c-bcl-2 - metabolism | Flow Cytometry | Bcl-2-Like Protein 11 | Apoptosis Regulatory Proteins - genetics | Membrane Proteins - metabolism | Forkhead Transcription Factors - antagonists & inhibitors | Melanoma - metabolism | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | RNA, Messenger - genetics | Proto-Oncogene Proteins - genetics | Forkhead Transcription Factors - genetics | Phosphatidylinositol 3-Kinases - genetics | Animals | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Myeloid Cell Leukemia Sequence 1 Protein | Apoptosis Regulatory Proteins - antagonists & inhibitors | Fluorescent Antibody Technique | Sulfonamides - adverse effects | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Proto-Oncogene Proteins c-bcl-2 - genetics | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Drug Resistance, Neoplasm - drug effects
Journal Article
Cancer Discovery, ISSN 2159-8274, 2013, Volume 3, Issue 2, pp. 158 - 167
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 4/2013, Volume 110, Issue 15, pp. 5957 - 5962
Journal Article
The EMBO Journal, ISSN 0261-4189, 03/2016, Volume 35, Issue 5, pp. 462 - 478
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2015, Volume 112, Issue 6, pp. E536 - E545
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 18, pp. 2792 - 2799
Abstract Background Acquired resistance to BRAF inhibitors (BRAFi) is a near-universal phenomenon caused by numerous genetic and non-genetic alterations. In... 
Hematology, Oncology and Palliative Medicine | Resistance | Vemurafenib | NRAS | Splice | Acquired | Dabrafenib | BRAF | MEK1 | MAPK | Meta-analysis | SURVIVAL | RAF INHIBITION | METASTATIC MELANOMA | THERAPY | ONCOLOGY | PATHWAY | COBIMETINIB | B-RAF | MUTATIONS | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - therapeutic use | Skin Neoplasms - enzymology | Time Factors | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Biomarkers, Tumor - metabolism | Female | Biomarkers, Tumor - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - metabolism | Skin Neoplasms - pathology | Genetic Predisposition to Disease | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Melanoma - pathology | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Phenotype | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Mutation | Australia | Melanoma - mortality | splice | vemurafenib | meta-analysis | resistance | amplification | spectrum | MEK2 | dabrafenib | acquired
Journal Article
Cancer Cell, ISSN 1535-6108, 06/2016, Volume 29, Issue 6, pp. 805 - 819
Journal Article